T lymphocyte-mediated suppression of myeloma function in vitro. II. Evidence for regulation of hapten-binding myelomas by syngeneic hapten- specific cytolytic T lymphocytes by unknown
T  LYMPHOCYTE-MEDIATED  SUPPRESSION  OF  MYELOMA 
FUNCTION  IN VITRO 
II.  Evidence for Regulation of Hapten-binding Myelomas by 
Syngeneic Hapten-specific Cytolytic T  Lymphocytes* 
BY  ABUL K  ABBAS, SHELDON  E. RATNOFSKY,  AND STEVEN J. BURAKOFF 
From the Departments of Pathology, Harvard Me&cal School and Peter Bent Brigham Hospital,  Boston, 
Massachusetts 02115 
It is now well established that regulatory helper and suppressor T  lymphocytes play 
a  critical  role  in  determining  the  magnitude  and  nature  of a  variety of immune 
responses.  Different  lines  of experiments  indicate  that  T  ceils  recognize not  only 
surface-bound antigens,  but  also  idiotypic (1,  2)  and allotypic (3)  determinants on 
helper  T  cells  and/or  B  lymphocytes.  In  addition,  it  is  clear  that  the  antigen- 
recognition  function  of several  classes  of T  lymphocytes,  including  helper  cells, 
cytolytic T  lymphocytes (CTL)1, and the effector cells of delayed hypersensitivity (4), 
is  restricted  by  the  major  histocompatibility  gene  complex  (MHC).  The  MHC- 
restricted collaboration between antigen-specific helper T  and B lymphocytes (5, 6) 
implies that antigen-specific T  cells recognize receptor-bound antigen in some form 
of an association with MHC  gene products, although it  is difficult to demonstrate 
directly such an associative recognition mechanism in normal immune-cell popula- 
tions. 
The  possibility  that  hapten-specific,  MHC-restricted  CTL  (7)  can  function  as 
regulators of anti-hapten immune responses has been raised by several investigators, 
although this has not been experimentally verified to date (8). Cytolytic T lymphocytes 
might specifically regulate humoral immune responses by recognizing receptor-bound 
antigen on B cells in association with self MHC determinants in a manner that may 
be analogous to  the  MHC-restricted  interaction between antigen-specific helper T 
and  B  lymphocytes. Schmitt-Verhulst  et  al.  (9)  and  Ballas  and  Henney (10)  have 
shown  that  2,4,6-trinitrophenyl  (TNP)-protein  conjugates  that  are  noncovalently 
bound to target cell surfaces can be recognized by syngeneie TNP-specific CTL. This 
phenomenon, however, occurs only with cells from mice of the H-2  k haplotype, and 
does not involve binding of TNP-proteins to specific anti-TNP receptors on the target 
cells  As one approach to directly studying the interactions between receptor-bound 
antigen and H-2-restricted T  lymphocytes, we have examined the effects of lympho- 
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cyte populations containing hapten-specific CTL on the function of hapten-binding 
myelomas  in  the  presence  of soluble  hapten-protein  conjugates.  In  this  system, 
myeloma cells are used as a homogeneous target cell population analogous in function 
and  receptor expression to normal B  lymphocytes or to antibody-secreting cells. In 
fact,  recent  experiments strongly suggest  that  myelomas  are  physiologically valid 
model systems for analyzing the regulation of normal immunocompetent lymphocytes 
(11,  12).  Thus, tolerogenic antigens  (13), antigen-antibody complexes (14), carrier- 
specific helper and suppressor T  cells (15,  16), idiotype-specific T  cells (17,  18), and 
alloreactive T  cells (19)  have all been shown to be capable of modulating myeloma 
cell  function.  The  specific  experimental  protocol  we  have  used  is  to  stimulate 
BALB/c lymphocytes with syngeneic TNP-modified cells, and then to examine the 
effect of the  TNP-reactive T  cells  generated  in  this  manner on  the  TNP-binding 
BALB/c myeloma, MOPC 315, in the presence of TNP-protein conjugates. We have 
used assays of antibody secretion by the myeloma as a readout system for measuring 
the effect of CTL. The rationale for this approach is that the inhibition of target-cell 
function seems to represent a pre-lytic effect of CTL, and is a far more sensitive assay 
for CTL activity than 51Cr release or trypan blue dye exclusion methods (19, 20). The 
basic  observations  that  have  been  made  are  that  TNP-reaetive T  cells  markedly 
inhibit antibody secretion by the myeloma in the presence of TNP-protein conjugates, 
although by ~tCr-release assays, the lysis of myeloma targets can be detected only if 
the  targets  are TNP  modified and  can  not  be detected in  the  presence of soluble 
antigen. The T  cells responsible for this functional inhibition possess the phenotypic 
characteristics of CTL, are hapten specific and H-2 restricted in their function, and 
suppress only myeloma cells that bear specific receptors for the hapten. In addition, 
preliminary experiments indicate that TNP-specific CTL also inhibit primary anti- 
body response to TNP-proteins in vitro. These findings are discussed in relation to the 
mechanisms  of T  lymphocyte-target cell  interactions  and  the  possible  physiologic 
immunoregulatory role of hapten-reactive T  lymphocytes. 
Materials and Methods 
Myeloma Cell Lines, Anttgens  The myeloma cell hnes used in this study are listed in Table I 
The majority of the experiments have been done with tissue-culture-adapted MOPC 315 cells, 
which were used in previous studies  and whose charaeterisucs have been described in detail 
(13)  Briefly, the cells secrete  an  IgA, X2 antibody specific for TNP and  2,4-dinitrophenyl 
TABLE  I 
Myeloma Cell Lines 
Cell hne  Form  Anubody product 
MOPC 315  Tissue culture, ascites 
TEPC  15  Ascites 
S t07  Tissue culture 
MPC 11  Tissue culture 
MOPC  104E  Ascites 
X5563  Tissue culture 
lgA, A2, antI-DNP and -TNP 
IgA, r, anti-phosphorylchohne 
IgA, r; anti-phosphorylchohne 
IgG2b, •,  unknown speclfioty 
IgM, h, anu-txl,3 dextran 
IgG~, i¢; unknown specificity 
All are BALB/c (H-2  d) myeloma hnes except for X5563 (C3H, H-2  k)  Tissue-culture- 
adapted MOPC 315 and X5563 cells were maintained at  37°C in Letbovltz (L-15) 
medmm with 2  mM  L-glutamme, penicillin, streptomycm, and  15%  FCS,  whereas 
S107  and MPC  11  cells were cultured  at  37°C in  5% CO2 in  Dulbecco's modified 
Eagle's medium with pemcilhn, streptomycin, and 20% FCS 308  CYTOLYTIC  T  LYMPHOCYTE  REGULATION OF MYELOMA CELLS 
(DNP), and, at  any time, 50-75%  of the cells express membrane  IgA receptors for TNP  as 
detected by rosette assays  The other tumor lines were obtained from the following sources' 
TEPC  15 from Dr. R. Germain, Harvard Medical School, Boston, Mass.; S107 from Dr. M. D. 
Scharff, Albert Einstein College of Medicine, Bronx, N  Y.; and MPC  11  from Dr  M  Gefter, 
Massachusetts Institute of Technology, Cambridge, Mass. 
TNP conjugates of keyhole limpet hemocyanm (KLH), bovine y-globuhn (BGG), and bovine 
serum albumin (BSA) were prepared by the method of Ballas and  Henney  (10)  using 2,4,6- 
trmitrobenzene sulfomc acid (TNBS)  in 0.4 M  borate buffer, pH 9. The conjugates used m 
these experiments were TNPlvKLH, TNP2sKLH, and TNPa0KLH  (17,  28, and 30 tool TNP, 
respectively, per  100,000  moi  wt  of KLH),  TNP52BGG  (52  mol  TNP/mol  of BGG),  and 
TNP~BSA (24 tool TNP/mol  of BSA)  DNPz0KLH was prepared by incubating KLH with 
2,4-dimtro-l-fluorobenzene in 1% sodium carbonate, p-Azobenzene arsonate (ABA) conjugates 
of KLH were prepared as described by Nisonoff (21).  The double conjugate TNP-ABA-KLH 
was prepared by incubating ABA-KLH with TNBS following the method of Ballas and Henney 
(10) as described above. 
Generatzon of  Hapten-reactwe T Cells and Assay  for Cytolysis  Normal BALB/c spleen lymphocytes 
(7  ×  10  e)  were stimulated in  vitro with 6  ×  106  syngeneic,  1,500-tad  x-irradiated, TNBS- 
modified, erythrocyte-free splenocytes as described previously (22)  Cultures were carried out 
for 5 d  in 2  ml RPMI-1640 supplemented with penicillin, streptomycin, and  10%  fetal calf 
serum (FCS) (Grand Island Biological Co., Grand Island N. Y.) in 16-mm Linbro wells (Linbro 
Chemical Co.,  Hamden,  Conn.)  at  37°C  in  a  humidified atmosphere of 5%  CO~.  In some 
experiments,  animals  were  primed subcutaneously  6-7  d  previously with  3  ×  107  TNBS- 
modified syngenelc cells, and their spleen lymphocytes boosted in vitro as described above. For 
generating DNP- and ABA-reactive T  lymphocytes, animals were always primed subcutane- 
ously with hapten-modified cells and spleen cells boosted in vitro, as described previously (23, 
24). Such stimulated cells are referred to as anti-hapten effector lymphocytes or hapten-speclfic 
CTL,  their detailed characterization is described in  Results  In addition, m  all experiments 
spleen cells were  cultured  in  parallel without  hapten-modified stimulators  (referred  to  as 
unstimulated lymphocytes). In some experiments, responder spleen cells were obtained from 
BALB/c mice that had been injected with 100 mg/kg eyelophosphamide intraperitoneally 2 d 
earlier. TNP-specific CTL were also induced in vivo by the method of Rollinghoff et al  (25) 
Briefly, BALB/c mice were injected with 100 mg/kg eyclophospbamide intraperitoneally, and 
7  3  d  later, were immunized  in  the hind  footpads with  3  ×  10  TNP-modified,  1,500-rad  x- 
irradiated syngeneic spleen cells. Draining lymph nodes harvested 4 d  later were used as the 
source of TNP-specified CTL  Unstimulated lymphocytes were obtained from lymph nodes of 
cyclophosphamlde-pretreated mice that were either not immunized or were injected in footpads 
7  with 3 ×  10  unmodified syngeneic splenocytes. 
Cytolytic activity of cultured cells was measured by 51Cr-release  assays, as described previ- 
ously (22).  For BALB/c (H-2  a) cells, the targets used were syngeneie 51Cr-labeled MOPC 315 
or P 815  (DBA/2) mastocytoma cells, modified with 10 mM TNBS (for assessing TNP-reactive 
CTL), 10 mM DNBS (for anti-DNP CTL), or p-azobenzene arsanilate (for anu-ABA CTL), all 
of which have been previously described (22-24)  AntI-TNP CTL gave comparable levels of 
lysls using TNP-modified MOPC 315 or P 815 cells as targets  For B 10 BR (H-2  k) effectors, the 
targets were SXCr-labeled TNBS-modified RDM-4  (AKR)  tumor cells  Assays were done at 
effector'target (E:T) ratios ranging from 4:1 to  100-1, for 4 h  at 37°C  in  10- ×  75-mm glass 
tubes, after which the 5aCr released into the supernate was counted  Results are expressed as 
percent specific lysis =  (E -  C)/(FT -  C), where E  -- release in experimental groups with 
CTL, C =  background release from targets with normal spleen cells, and FT -- maximal release 
after four cycles of freezing and thawing. 
Myeloma-Cell Cultures and Assays  for Anttbody Secretwn  Viable tissue-culture-adapted myeloma 
cells (>90% viable by trypan blue dye exclusion) were purified by centrifugatlon over Ficoll- 
Isopaque (Pharmacia Free Chemicals, Div. of Pharmacia, Ine, Piscataway, N  J  )  (13),  and 
ascitic cell lines were freed oferythrocytes by lysis with Tris-buffered 0.83% ammonium choride, 
pH 7.4  In all experiments, 105 myeloma cells in triplicate were first incubated with or without 
the appropriate concentration of antigen  (hapten  conjugates of KLH)  in  RPMI-1640  with 
penicillin, streptomycin, 10% FCS, 5 ×  10  -s M  2-mercaptoethanol, and  10 mM Hepes  These A  K  ABBAS, S  E  RATNOFSKY, AND S. J.  BURAKOFF  309 
incubations were done in round-bottomed microculture plates (Linbm Chemical Co.) at 37°C 
in 5% CO2  At the end of 60 rain, lymphocytes generated by in vitro culture as described above 
were added to a final vol of 0.2 ml, and the incubations continued for a further 4-48 h  At the 
end  of this coculture,  cells were  harvested,  washed  three  times,  and  assayed  for antibody 
secretion as described below. In all experiments, control groups of myeloma cells alone and 
myeloma cells with antigen alone were included; the antigens chosen have been shown to have 
no significant effect on myeioma growth or function ([13]; and these experiments). 
Antibody secretion was measured by a  reverse hemolytic plaque assay (26),  the details of 
which have been described previously (13,  19). Briefly, 1/50ths or  1/100ths of eacda washed 
culture were mined with 20 pl of 30% sheep erythrocytes coated with staphylococcal protein A, 
20/~i of an optimal concentration of developing serum, 20 pl of a  1:3 dilution of guinea pig 
complement (Pel-Freeze Biologicals Inc., Rogers, Ark.), and 300 gl of 0.5%  agarose in Hanks' 
balanced salt solution. The mixture was smeared on a  10-era plastic dish, incubated at 37°C m 
a humidified atmosphere for 5-6 h, and the plaques counted. The developing sera used were: 
1:50  dilution of rabbit  anti-M315  IgA for  MOPC  315,  S107,  and  TEPC  15  cells  (all IgA 
secretors), 1:50 rabbit anti-MPC  11  for MPC  11  cells, and  1:50 rabbit anti-104E for MOPC 
104E  cells  Each myeloma cell line produced plaques only with the appropriate developing 
serum; moreover, cultured lymphocytes by themselves did not produce significant numbers of 
plaques under these conditions. All results are expressed as plaque-forming cells (PFC)/culture 
Statistical analyses and determinations of the percent inhibition caused by hapten-reactive cells 
are calculated using groups lacking the effector lymphocytes as controls. 
Binding of tZSl-labeled  Antzgens to Myeloma Cells.  The techniques have been described previously 
(27). Briefly, TNP-KLH was trace-labeled with 12s  -  •  -  125  I by the chloramme T  method. Free  I was 
removed  by  exhaustive  dialysts, and  >90%  of the  radioactivity was  precipitable m  10% 
trichloroacetic acid. 10  n myeloma cells were incubated in duplicate with various concentrations 
of 125I-labeled antigen in 0.2 ml of RPMI-1640 with supplements in 12- ×  75-ram plastic tubes 
at  37°C  in  5%  CO2.  After  1-2  h,  cells were  washed  four  times,  and  the  cell-associated 
radioactivity measured  in  a  Beckman  Biogamma II -/-counter (Beckman  Instruments,  Inc., 
Spinco Div., Palo Alto, Calif). Standards wtth  known amounts of lasI-labeled antigen were 
mcluded, and results are expressed as nanograms of antigen bound/'I0  b cells. For ascitic lines, 
macrophages were depleted by two cycles of adherence to plastic dishes, each for 45 min at 
37°C, before antigen incubations. 
lnductwn  of Antz-TNP  Anttbody  Responses In  Vttro.  A  microculture  system  was  used  for 
generating primary anti-TNP antibody responses (28).  5  ×  10  n normal BALB/c spleen cells 
were cultured with TNP-KLH in 0.2 ml of RPMI-1640 with supplements as described above. 
Cultures were done in triplicate in fiat-bottomed microculture plates (Linbro Chemical Co.) in 
5% CO2 at 37°C  for 4 d, after which each well was harvested, washed twice, and anti-TNP 
PFC assayed by the slide modification of  the Jerne method using TNP-coated sheep erythrocytes 
as indicator cells. Preliminary experiments established that, in our hands, the optimal concen- 
tration of TNP-KLH  was  20-25 p.g/ml; unconjugated  KLH  elicited no  response;  the  PFC 
response was T  cell dependent;  only IgM  PFC  were observed;  and  the  response was TNP 
specific (>95% inhibttion with 3 ×  10  -4 M  TNP in the form of TNP~BSA). 
Other Techmques.  Effector lymphocytes were treated with anti-Thy- 1 serum and complement 
as follows' tn vitro generated effector lymphocytes were treated with a monoclonal anti-Thy- 
1.2 antibody (a gift of Dr. Ann Rothstein, Massachusetts Institute of Technology), followed by 
rabbit complement (Pel-Freeze Biologicals Inc ). Cells were washed, counted with trypan blue, 
and used m cocultures. Effector cells were also treated with a monoclonal anti-Ly-2 2 antibody 
(a gift of Dr  Paul Gottlieb, Massachusetts Institute of Technology) plus complement  Controls 
consisted of complement treatment alone. 
Results 
Effect  of  TNP-reactwe  Lymphocytes  on  MOPC  315  Cells.  In  the  initial  series  of 
experiments, BALB/c spleen cells stimulated in  vitro with syngeneic TNP-modified 
splenocytes were tested  for their ability to lyse 51Cr-labeled MOPC  315  cells in  the 
presence  of 50-100  pg/ml  of TNP-KLH  or TNP-BGG.  Although  such  stimulated 310  CYTOLYTIC  T  LYMPHOCYTE REGULATION OF MYELOMA CELLS 
lymphocytes efficiently lysed TNP-modified  MOPC  315  ceils,  we  were  unable  to 
detect  any  cytolysis of MOPC  315  targets  incubated  with  soluble  hapten-protein 
conjugates in a 4-h assay. In addition, MOPC 315 cells incubated with soluble antigen 
could not serve as cold targets to block the iysis of 51Cr-labeled TNP-modified MOPC 
315  targets  (data  not  shown).  We  then  tested  the  effect of this  anti-TNP  CTL- 
containing lymphocyte population on antibody secretion by MOPC 315 cells in the 
presence of TNP-KLH, an antigen which by itself does not  affect MOPC  315 cell 
function. As shown in Table II, TNP-reactive lymphocytes (anti-TNP effector cells) 
significantly suppress IgA secretion by the myeloma cells in the presence of 10 or 50 
#g/ml of TNP-KLH, whereas BALB/c splenocytes cultured in parallel, but without 
TNP-modified stimulators (unstimulated effector cells), are not suppressive. In addi- 
tion, the TNP-reactive cells capable of inhibiting myeloma function are radioresistant, 
and can also be generated by in vitro stimulation of spleen cells from mice pretreated 
with  100  mg/kg of cyclophosphamide (Cyclo)  (Table II).  Moreover, TNP-reactive 
cells are incapable of suppressing MOPC 315 cells in the absence of soluble antigen 
(Table III). In most of the experiments, the degree of suppression observed is 40-65%. 
This may be because only 50-75% of MOPC  315 cells express TNP-specific surface 
receptors by rosette assays.  Attempts  to determine  if PFC  are  present  only in  the 
receptor-bearing  fraction  or  if they  are  distributed  among  receptor-positive  and 
-negative myeloma cells have produced inconclusive results so far.  In some experi- 
ments, we have found that  BALB/c spleen cells cultured  in  FCS-containing media 
without additional stimulators are suppressive for MOPC 315 cells, but this suppres- 
sion is seen with or without the presence of TNP-proteins. This nonspecific suppression 
is eliminated by irradiating the effector cells, a  procedure that  has no effect on the 
lyric activity of TNP-reactive cells.  Moreover, the consistent  inability of anti-TNP 
effectors to suppress MOPC  315 cells in the absence of soluble antigen provides an 
additional specificity control. 
In addition to the inhibition of IgA secretion described above, cocultures of MOPC 
315 cells with TNP-KLH and anti-TNP effector lymphocytes show a  15-25% reduc- 
tion in viable myeloma-cell recovery after 24 h. After washing and reculture in fresh 
medium for 2-3 d, viable MOPC 315 cell recovery in these groups is reduced by 40- 
50% compared to groups with myeloma cells alone or myeloma cells and anti-TNP 
effectors without  antigen.  Taken together, these results suggest  that  the  functional 
suppression of myeloma targets is a  pre-lytic event reduced by the CTL, eventually 
resulting in reduced viable myeloma-cell recovery. Because, in this system, measure- 
ment of myeloma-cell function gives the most consistent and reproducible results, and 
because a similar assay has been used by other investigators to study CTL-target cell 
interactions (19, 20), we have used PFC assays to analyze the nature of the interaction 
between anti-TNP effector cells and myeloma targets, in all subsequent experiments. 
Properttes of TNP-reactwe  Effector Cells.  The data in Table II have shown that  the 
TNP-reactive lymphocytes that suppress MOPC 315 cell function are radioresistant, 
and their precursors are insensitive to Cyclo These cells are T  lymphocytes, as judged 
by their sensitivity to  treatment  with  anti-Thy-l.2 serum  and  complement  (Table 
IV)and their nonadherence to nylon wool (data not shown). Moreover, the cells bear 
Ly-2.2 antigens, as shown by antiserum and complement treatment  (Table IV). In a 
series  of kinetics  and  dose-response  experiments,  we  have  found  that  significant 
suppression  requires >4  h  coculture of 10s-3  X  105 effector lymphocytes with  10  '~ A  K.  ABBAS,  S  E  RATNOFSKY, AND  S. J  BURAKOFF 
TABLE  II 
Inhtbttmn of MOPC 315 Cells by TNP-reactwe Lymphocytes 
311 
Effeetor cells  IgA PFC/cul- 
(3 X l0  s)  TNPITKLH  ture (mean :1:  P*  Inhabition:]: 
SE) 
X  I0 -a  % 
None  None  67 5 ±  6 9  --  -- 
None  10 #g/ml  60.1 ±  2 8  --  -- 
None  50 #g/ml  55 3 ±  6 9  --  -- 
Anti-TNP  10 #g/ml  28 4 +  1 2  0 005  52.7 
Anu-TNP  50 v.g/ml  23.0 ±  5.2  0 007  58.4 
Unstimulated  50 #g/ml  48 7 :t: 3 5  NS§  11.9 
Anti-TNP, Cyclo  10 #g/ml  33 2 "4- 4.5  0.01  44 8 
pretreated  50 #g/ml  32 1 :t: 2 1  0 008  42.0 
Unstlmulated, Cyclo  50 ~.g/ml 
pretreated 
59 7 ±  7.7  NS  0 
Anu-TNP,  1,500 rad  10 #g/ml  28 8 ±  1 2  0 005  52  1 
x-irradiated  50 #g/ml  24.3 ±  4 2  0 006  56 1 
Unsumulated,  1,500  50 #g/ml  45 2:1:4 7  NS  18 3 
tad x-trradlated 
Effector cells 
Assay for cytolysls of nlcr-labeled, TNP-modl- 
fled P 815 targets  specific lysis at E T]] 
ll  1  33.I  100  1 
'7~ 
Anti-TNP  47.5  77.2  88.3 
Unsttmulated  16 0  26.9  45 5 
AntI-TNP, Cyclo pretreated  14 6  30 0  50 7 
Unstimulated, Cyclo pretreated  1 4  0 0  1 8 
105 MOPC 315 cells were cultured for 24 h in triplicate alone, with TNP17KLH,  or 
with TNP17KLH and 3 ×  l0  s viable lymphocytes generated by in vttro stimulation 
of BALB/c spleen cells wath syngeneic TNP-modified cells (ami-TNP), or control 
cells cultured by themselves  (unstimulated)  Effector cells were also- (a) generated 
with spleen cells from mice pretreated with Cyclo,  or (b) x-irradiated (I,500  rad) 
before adding to myeloma targets. 
* Calculated by Student's t  tests,  using groups that contained myeloma cells and 
equivalent concentration of TNPj7KLH without effector cells as controls. 
~: Determined using groups that contained myeloma cells and anttgen only as controls 
(i e, 100% response) 
§ NS, not sigmficant  (P >  0.05) 
]1 Spontaneous release was 8 4%, unmodified  SICr-labeled targets showed no significant 
lysis 
myeloma targets, and is consistently seen after 24 or 48 h  (data not shown). Moreover, 
the anti-TNP  effector cells can he generated by in vitro stimulation in 0.5% syngeneic 
mouse serum or 2% rat serum, indicating that their activity is not related to the FCS 
in the culture medium. 
H-2 Restnctzon  of Ant,-TNP Effector  Cells.  To  determine  if the  anti-TNP  effector 312  CYTOLYTIC  T  LYMPHOCYTE  REGULATION  OF  MYELOMA  CELLS 
TABLE  III 
TNP-reactwe Cells Suppress MOPC 315 Cells Only zn the Presence of 
TNP-KLH 
Effector cells  IgA PFC/culture  p.  Inhmbition 
(3 x  105)  TNPzaKLH  (mean +  SE) 
×  10 -a  % 
None  None  42 3 :t: 1 9  --  -- 
None  50/tg/ml  42 7 +  l 8  --  -- 
Ant~-TNP  50/xg/ml  24 3:1:  I 4  <0.001  43 1 
Antt-TNP  None  42.0 +  3 7  >0.9  0 7 
105 MOPC 315 cells were cultured for 24 h with or wtthout TNP~KLH and 
1,500-rad  x-irradiated  BALB/c  anti-TNP  effector lymphocytes that  were 
generated  m  vitro.  Data  are pooled  from  five experiments, each  done  m 
triplicate, the group showing slgmficant inhibition ms ltaliozed. 
* Calculated as m Table II 
TAaLE  IV 
Surface Propertzes of TNP-reacttve Lymphocytes 
Effector cells  IgA PFC/cul- 
(10 ~)  Treatment  TNP2sKLH  ture (mean +  P*  Inhibition* 
SE) 
X  I0 -a  % 
None  None  76 7 :f: 3 7  --  -- 
None  50 ~g/ml  73 1 :t: 2 1  --  -- 
AntI-TNP  None  50 btg/ml  44 0 +  5 7  <0 01  39.8 
Ant~-TNP  Anti-Thy-1 2 +  C  50 p.g/ml  64 4 +  5 2  NS~:  11 9 
Anti-TNP  Anti-Ly-2 2 +  C  50 pg/ml  76 5 ±  4 4  NS  0 
Antm-TNP  C  50 pg/ml  403 +  1 9  <0001  449 
Effector cells  Treatment 
Assay for cytolysls of 51Cr-labeled, TNP-mod]fied P 815 
targets, speofic lysts at E T§ 
11  1  33  1  100  1 
Unsttmulated  None  0 7  2 4  11 2 
Ann-TNP  None  5 0  17 5  37 0 
Anti-TNP  Ant~-Thy-I 2 +  C  1 2  5 2  8 2 
Ant]-TNP  Anti-Ly-2 2 +  C  2 8  0  2 8 
Anti-TNP  C  5 5  18 2  37 9 
10  ~ MOP(:  315  cells were cultured  for  24  h  with or  wkthout  TNP-KLH  and  1,500-rad  x-irradiated 
BALB/c anti-TNP effector cells which were generated m vitro, and treated as shown  C, complement 
* Calculated as in Table II 
:~ NS, not slgmficant 
§ Spontaneous SlCr release  9 3% 
lymphocytes  are  H-2  restricted  (similar  to  hapten-specific  CTL  described  in  other 
systems  [7,  9,  10,  22-24]),  we  tested  the  effects  of  CTL  generated  with  spleen 
lymphocytes  of different mouse  strains on the myeloma  targets. As shown  in Table  V, 
B10.BR  (H-2 k)  anti-TNP  CTL  do  not  affect  the  function  of  MOPC  315  (H-2 a) 
targets, whereas  syngeneic  BALB/c  anti-TNP  CTL  are suppressive  in the presence  of 
TNP-KLH.  Because  no  TNP-binding  myeloma  of an  H-2  type  other  than  H-2 a  is 
available,  the  reciprocal  coculture  is  not  feasible.  As  a  further  verification  of  H-2 A  K  ABBAS, S  E  RATNOFSKY, AND S. J.  BURAKOFF 
TAeLg V 
H-2 Restrzctzon of TNP-reactwe Effector Cells 
313 
Effector cells  IgA PFC/cuhure 
(3 ×  10  t)  TNPzsKLH  (mean + SE)  P  Inhibition 
×  10 -a  % 
None  None  40 6:1:2 4  --  -- 
None  50 #g/ml  44 1 :t: 2.5  --  -- 
BALB/c antt-TNP  50 #g/ml  25 4 -4- 2 4  <0 001  42 4 
BALB/e anti-TNP  None  48 8:1:3.3  NS*  0 
B 10 BR anti-TNP  50 #g/ml  48 4:1:5 7  NS  0 
BL0.BR antt-TNP  None  48.6 "4- 5 7  NS  0 
Effector cells 
Assay for cytolysis of 5~Cr-labeled,  TNP-modified  P 815 (H-2  d) and RDM4 
(H-2  k) targets- speofie lysls of:~ 
TNP-P 815 at E T  TNP-RDM4 at E'T 
11.1  33.1  100:1  11:1  33.1  100.1 
% 
BALB/c anti-TNP  8 1  15.4  32 8  2.8  11 5  21 8 
BI0.BR anu-TNP  2 1  4 2  9 4  23.3  41 8  57 6 
l0  s MOPC 315 cells were cultured for 24 h with or wtthout  TNP-KLH and  1,500-rad x-,rradiated 
BALB/c or BI0.BR antt-TNP effector lymphocytes that were generated  m vitro. Data are pooled from 
two experiments and expressed as m Table II 
* NS, not s]gnaficant (P> 0 1) 
:~ Spontaneous 51Cr release was <20% 
restriction, we attempted to block the effect of BALB/c anti-TNP effector lymphocytes 
on MOPC  315 cells with cold targets; in this system, cold targets refer to tumor ceils 
that do not secrete IgA and are, therefore, not detected in the PFC assay. As shown 
in Table VI, TNP-modified MPC  11  and P815  (H-2  a)  cells block the suppression of 
MOPC  315 cells by BALB/c anti-TNP CTL  in the presence of TNP-KLH,  whereas 
TNP-modified  X5563  (H-2  k)  or  unmodified  "cold  targets"  have  no  effect.  These 
experiments establish that the anti-TNP effector cells detected in this system are H-2 
restricted,  and,  taken  together  with  the  phenotypic  characteristics detailed  above, 
strongly suggest that the effector ceils are, indeed, hapten-reactive CTL. 
Hapten  Speczficzty  of CTL.  The  experiments  described above  have  demonstrated 
that  inhibition of MOPC  315  cell function  is seen with TNP-reactive but  not  with 
unstimulated cells, and only in the presence of appropriate TNP-protein conjugates, 
suggesting that  the phenomenon  is hapten-specific. As a  more stringent  control  for 
specificity, T  cells were generated by priming in vivo followed by in vitro stimulation 
with  DNP-  and  TNP-modified  syngeneic  splenocytes.  These  hapten-reactive  CTL 
were tested for cytolysis of hapten-modified 5XCr-labeled targets and  for their effects 
on MOPC  315 cells in the presence of DNP-KLH  or TNP-KLH.  In our hands, anti- 
DNP CTL lyse both DNP- and TNP-modified syngeneic targets, whereas anti-TNP 
CTL lyse only TNP-modified targets (Table VII) (R. Finberg, M.-S. Sy, M. I. Greene, 
and  S. J.  Burakoff.  Manuscript  in preparation.)  Consistent with this pattern, TNP- 
specific CTL  inhibit  MOPC  315  cells only in  the presence of TNP-KLH,  whereas 
DNP-specific  CTL  cause  significant  suppression  in  the  presence  of both  hapten- 
protem conjugates,  TNP-KLH  and  DNP-KLH  (Table VII).  Using antigens  trace- 314  CYTOLYTIC T  LYMPHOCYTE  REGULATION OF MYELOMA CELLS 
TABLE  VI 
Cold-Target  Block,ng  of Inh,bztzon of MO  PC 315 Cells by BALB/  c TNP-reactwe Lymphocytes 
Experi-  Effector cells  IgA PFC/cul- 
ment  (3 X l0  s)  TNPa0KLH  Cold targets (5 ×  l0  s)  ture (mean ±  P  Inhlbmon 
SE) 
×  10 -~ 
1  None  None  None  25.6 +  1 2  --  -- 
None  50 ~g/ml  None  24.9 +  1 4  --  -- 
Antt-TNP  50/tg/ml  None  124  ±  08  <001  502 
AntI-TNP  None  None  21 7 ±  1 5  NS*  15 2 
Anti-TNP  50/xg/ml  TNP-MPC 11  (H-2 d)  21 2 ±  2 6  NS  14 9 
Anu-TNP  50 ~tg/ml  TNP-P815 (H-2  d)  24 9 ±  1 2  NS  0 
AntI-TNP  50 ~g/ml  TNP-X5563 (H-2 k)  14 7 ±  1 6  <0 01  41 0 
Ant,-TNP  50/tg/ml  MPC l 1  13 5 ±  1 3  <0 005  45 8 
Anti-TNP  50 p.g/ml  P 815  8 7 ±  0 7  <0 001  65 1 
2  None  None  None  51 6 +  2 6 
None  50/.tg/ml  None  55 9 +  4 1 
m 
AntI-TNP  50/xg/ml  None  162 +  50  <00l  71 0 
Ant,-TNP  None  None  46.6 ±  5.8  NS  9 7 
Anu-TNP  50/tg/ml  TNP-MPC  11  41 8 ±  4.6  NS  25.2 
Anu-TNP  50/tg/ml  MPC 11  170 +  46  <001  696 
l0  s MOPC  315  cells were cultured  in  trlphcate with or without  TNPa0KLH,  1,500-rad  xqrradlated 
BALB/c anti-TNP effector cells, and 5,000-rad  xqrradiated TNP-modified or unmodifed "cold targets" 
for  16 h  (experiment  l)  or 24 h  (experiment  2)  Data  are expressed  as m  Table II; groups  showing 
significant  inhibition are ltalicmed  In all experiments cold targets alone or with TNP-specific CTL, but 
without TNPa0KLH, had no effect on IgA PFC  ("Cold targets" refers to tumor cells not secreting IgA ) 
* NS, not significant 
labeled  with  125I, we  have  found  that  at  equivalent  concentrations  comparable 
amounts  of DNP20KLH  and  TNP2aKLH  are  bound  to  MOPC  315  cells  (data  not 
shown).  Therefore,  the  differences  in  the  effects  of  DNP-  and  TNP-specific  CTL 
cannot  be attributed  to differences in the amount  of antigen  bound  to the myeloma 
targets  and  presumably  reflect  inherent  differences  in  the  recognition  or  reactivity 
patterns  of the T  cells themselves. 
Requzrement for  Hapten-bmdmg  Receptors  on  Myeloma  Targets.  To  determine  if non- 
TNP  binding  H-2  d myelomas incubated  with TNP-KLH  could also be inhibited  by 
TNP-specific CTL, we tested a  battery of tissue-culture-adapted  and ascitic-myeloma- 
cell lines in this system.  The  data  in Table  VIII show that  tissue-culture-adapted  or 
ascitic  MOPC  315  cells  can  be  consistently  suppressed  when  incubated  with 
TNP2aKLH  and TNP-specific CTL.  However, under identical conditions,  S 107  (IgA, 
r;  anti-phosphorylcholine)  and  MPC  11  (IgG2b,  ~¢;  of unknown  specificity)  tissue- 
culture-adapted  lines,  and  TEPC  15  (IgA,  r;  anti-phosphorylcholine)  and  MOPC 
104E  (IgM,  ~k,  anti-dextran)  ascitic cells are  not  significantly  inhibited.  In  all  these 
experiments, antigen alone or TNP-specific CTL  alone are nonsuppressive.  Moreover, 
all the myeloma cell lines tested, when directly haptenated,  can be lysed by syngeneic 
TNP-specific CTL  in ~lCr-release assays.  Finally, when  mixtures of MOPC  315  cells A.K  ABBAS,  S  E  RATNOFSKY, AND S  J  BURAKOFF 
TAnLE  VII 
Speafiaty of TNP- and DNP-reactwe CTL 
315 
Effector cells  IgA PFC/culture 
(3 X 10~  Antigen (50 pg/ml)  (mean ± SE)  P  Inhibition 
×  10 -a  '7¢ 
None  None  82 5 ±  4 6  --  -- 
None  TNP~KLH  86 5 ±  4 7  --  -- 
None  DNP~KLH  85 6 ±  3 7  --  -- 
Anti-TNP  TNP~KLH  48.7  ±  6 l  <0 005  43 7 
AntI-DNP  TNP~KLH  37 2  ±  4 4  <0 001  57 0 
Unsttmulated  TNP2sKLH  76 9 ±  3.9  NS*  11  1 
Anu-TNP  DNP2oKLH  72 9 +  4 4  NS  14 8 
Antt-DNP  DNP2oKLH  53.2  +  4 0  <0,005  37 9 
Unsttmulated  DNP20KLH  80 7 +  4 2  NS  5 7 
AntI-TNP  None  73 9 ±  11.6  NS  10 4 
Ann-DNP  None  82 0 -1- 3 8  NS  0 6 
Unstlmulated  None  80 7 ±  2 5  NS  2 2 
Assay for cytolysts of 51Cr-laheled TNP- and DNP-P 815 targets  speofic lysls of:t: 
Effector cells  TNP-P 815 at E T  DNP-P 815 at E T 
11.1  33  1  100  1  11  1  33  1  100  1 
'7, 
Unstlmulated  4 1  11 4  18 3  0 6  12 0  21 6 
Anu-TNP  47 4  68 9  71 2  0 3  11 2  25 7 
Ant~-DNP  10.9  33.5  49.2  28.0  56 l  73 7 
105  MOPC  315  cells  were  cultured  for  24  h  with  or  wtthout  antigens  and  1,500-rad  x-irradiated 
BALB/c effector cells  that  were generated  by subcutaneous  priming and  m  wtro boosting.  Data  are 
expressed as m Table II, groups  showing slgmficant mhibluon are ltahclzed 
* NS, not sigmficant (P >  0 1) 
Spontaneous SICr-release was < t 5%. 
and  MPC  11  cells are cultured  with  TNP-KLH  and  syngeneic  TNP-specific  CTL, 
only IgA secretion is suppressed  (data not shown), indicating that there is no bystander 
effect on the non-TNP-receptor-bearing, IgG-producing MPC  11 targets. The inability 
to  suppress  non-TNP-binding  myelomas  in  the  presence  of TNP-KLH  cannot  be 
simply  attributed  to  differences  in  total  binding  of antigen  to  the  myeloma  cells, 
because,  at least over 1-2 h, approximately  equivalent amounts of antigen are bound 
to all the ussue-culture-adapted  lines or the ascitic lines tested at the same concentra- 
tion  (Table  VIII  B).  In  cold-antigen-competition  experiments,  we  have  found  that 
the binding of ~25I-TNP-KLH to MOPC  315 cells can be inhibited by 34-48%  in the 
presence of a  10 fold higher concentration  of unlabeled TNP52BGG,  which  is similar 
to previously published results (27). In contrast, the binding of 125I-TNP-KLH to non- 
TNP-binding  myelomas  can  only  be  blocked  by  10-20%  with  cold  TNPs2BGG, 
implying  that  much  of  this  binding  is  not  to  hapten-specific  surface  receptors. 
Nonspecific binding of ~2~I-labeled hapten proteins to tumor targets has been observed 
by other investigators, although the biochemical explanation for this is unknown.  For 
instance,  Bystryn  et  al.  (29)  found  comparable  binding  of 125I-DNP-BSA  to  MOPC 316  CYTOLYTIC T  LYMPHOCYTE  REGULATION  OF MYELOMA CELLS 
TABLE VIII 
TNP-spec~fic CTL Fad to Suppress  Non-TNP-bmdmg Myelomas 
Myeloma cells incubated 
with  MOPC 315 
(colture) 
A Percent  suppression  of antibody secretion 
MPC 11  SI07  MOPC 315  TEPC 15  MOPC 104E 
(culture)  (culture)  (ascites)  (ascttes)  (ascites) 
mean ±  SE 
TNP-KLH  10 #g/ml +  46 7 ±  5 7  ND*  ND  ND  ND  ND 
3 ×  105 anti-TNP cells 
TNP-KLH50#g/mI+  452±20  42±26  99±99  552±84  115±67  66±21 
3 ×  105 anu-TNP cells 
3x 105 antl-TNP cells  100±3.3  23±23  0  101 ±  10.1  73± 73  0 
B. Nanograms TNP-KLH bound/10  g cells 
MOPC 315  MPC l 1  S107  MOPC 315  TEPC  15 
(culture)  (culture)  (culture)  (ascates)  (ascites) 
mgan 
~2SI-TNP2sKLH l0 #g/ml  86.8  72 7  73 6  29 5  23 5 
~zSI-TNP~sKLH 50 #g/ml  325 0  252.8  249.4  93.7  115.8 
In A, 10  s BALB/c myeloma cells were cultured m triphcate with TNP-KLH and 3 ×  105 1,500-rad x- 
irradiated BALB/e anti-TNP effector lymphocytes for 24 h and then assayed for antibody secreuon 
Data  are normahzed and expressed as the percent suppression of PFC compared to groups lacking 
effeetor cells In all experiments, TNP-KLH alone had no significant effect on PFC  All the myeloma 
hnes have been tested at least three times. Statistically slgmficant results (P < 0 05 m each expenment) 
are ltahcmed. In B, the same tumor lines were incubated with ~mI-TNP2aKLH  for 1 h (asciuc cells) or 2 
h (tassue-culture-adapted  hnes) at 37°C, washed, and the cell-bound radioactivity measured  Each cell 
hne has been assayed two to six umes 
* ND, not done 
315 cells and control cells that  lack receptors  for DNP  in the absence of unlabeled 
carrier protein. The important result relevant to the present experiments is that such 
nonspecific binding does  not permit TNP-specific CTL to  interact with non-TNP- 
binding myeloma  targets.  In  fact,  TNP-specific  CTL  suppress  MOPC  315  cell 
function when soluble-antigen concentrations are as low as  10 #g/ml (Table II and 
Table VIII), but fail to suppress the non-TNP binding myelomas even at a  fivefold- 
higher antigen concentration. These results indicate that TNP-KLH  bound only to 
TNP-specific receptors  sensitizes target  cells so  as  to  render them  suppressible by 
TNP-reactive CTL. 
As an additional approach to this question, we tested the ability of ABA-KLH and 
the double conjugate TNP-ABA-KLH to sensitize tissue-culture-adapted MOPC 315 
cells for suppression by ABA-specific CTL. As shown in Table IX, TNP-specific CTL 
in the presence of TNP-KLH, but not ABA-KLH, suppress MOPC 315 cells, whereas 
ABA-reactive CTL are ineffective even in the presence of 100 #g/ml of ABA-KLH or 
TNP-KLH. This phenomenon is also not evidently attributable to the total amount 
of antigen bound to myeloma targets, because at  50 and  100 #g/ml, the amount of 
ABA-KLH bound/105 MOPC 315 cells in 1 h is 183.6 and 245.1 ng, respectively.Thus, 
the total amount of ABA-KLH bound to the cells at  100 #g/ml is greater than the 
amount of TNP-KLH bound at  10/~g/ml and roughly comparable to the amount of 
TNP-KLH bound at 50 #g/ml. However, when MOPC 315 cells are incubated with 
the  double conjugate TNP-ABA-KLH so  that  the  ABA  determinant is  bound to A  K  ABBAS,  S  E  RATNOFSKY,  AND  S  J.  BURAKOFF 
TABLE  IX 
Effect on ABA-spectfic CTL on MOPC 315 Cells 
317 
Effector cells  Antigen (t00 pg/ml)  IgA PFC/culture  (mean ±  SE)  P  Inhibition 
×  10  -3 
None  None  75 9 +  4 9 
None  TNP~KLH  72.7 +  5 2 
None  ABA-KLH  68 1 =1= 5.6 
None  TNP-ABA-KLH  75.4 ±  3 7 
Anti-TNP  TNP2sKLH  44 1 +  3 5 
Anu-ABA  TNP2sKLH  69.0 ±  7.3 
Anu-TNP  ABA-KLH  55 9 :t: 6.4 
Anti-ABA  ABA-KLH  64.8 "¢" 3.5 
Anti-TNP  TNP-ABA-KLH  42 4  ±  1 9 
Anti-ABA  TNP-ABA-KLH  45 0  ±  3.1 
Anti-TNP  None  68.3 ±  5.9 
Anti-ABA  None  71 6 ±  5 9 
% 
m 
<0 001  39.3 
NS*  5 1 
NS  17.9 
NS  4 8 
<0 001  43 8 
<0.001  40.3 
NS  10 0 
NS  5 7 
Assays for cytolysls of 51Cr-labeled,  TNP- and ABA-modified P 815 targets  specific 
lysis of~: 
Effector cells  TNP-P 815 at E.T  ABA-P 815 at E:T 
11  1  33'1  100  1  11  1  33.1  100  1 
% 
AntI-TNP  13 3  30 0  64 0  1 4  3 9  7 3 
Anu-ABA  2.7  7 1  22 4  45 8  70 1  87 6 
Unsumulated  -0 1  -0 1  5.9  0 3  1 3  1.2 
IO  s MOPC 315 cells were cultured for 24 h with 100 pg/ml of the anugens as shown, with or without 3 
×  105 (in two experiments) or 5 ×  105 (m one experiment) 1,500-rad  x-irradiated TNP-reactive or ABA- 
reactive BALB/c lymphocytes generated by subcutaneous priming and in vitro boosting Groups showing 
significant suppression of IgA secretion by MOP(:: 315 cells are italicized. Data are pooled from three 
experiments, using two batches of TNP-ABA-KLH  in each, statistical analyses and percent inhibition 
are calculated as in Table II. 
* NS, not sigmficant (P >  0 1) 
Spontaneous 5'Cr-release was <20%. 
TNP-specific  receptors, they become  susceptible to suppression by both TNP-specific 
and ABA-specific CTL  (Table IX). This experiment  provides strong confirmation  for 
the central role of binding  of antigens to specific receptors in this phenomenon. 
Effect  of  TNP-spec~c  CTL  on  Pnmao,  Antz-TNP  Antibody  Responses.  Preliminary 
experiments  have  shown  that  TNP-specific  CTL  generated  in  vitro  and  in  vivo 
markedly  suppress the primary  antibody  response of normal  syngeneic spleen cells to 
TNP-KLH  in vitro  (Table X).  The  effector cells are radiation  insensitive, and  their 
precursors are resistant to treatment  with Cyclo; and  unstimulated  lymphocytes  from 
Cyclo-pretreated  mice  have  no  effect  on  anti-TNP  PFC.  In  other  experiments,  we 
have  found  that  the  effector  cells  are  Thy-l.2-bearing  T  cells,  and  they  cannot  be 
bound  to plastic dishes coated with TNP52BGG  (data not shown). Studies are now in 318  CYTOLYTIC  T  LYMPHOCYTE  REGULATION  OF  MYELOMA  CELLS 
TAaLE  X 
Inhtbttwn  of Przmary Antt-TNP Antibody Responses by TNP-reactwe  CTL 
lgM antl-TNP 
Experiment  Effector cells  PFC/cult ure  P 
mean ± SE 
None  69 ±  10  -- 
AntI-TNP (5 ×  102)  21  ±  9  <005 
AntI-TNP (5 x  104)  10 ±  1  0 005 
Unstlmulated (5 ×  t02)  57 ±  13  NS* 
Unstlmulated (5 ×  104)  16 ±  8  0 03 
AntI-TNP, Cyclo pretreated (5 ×  102) 
Antl-TNP, Cyclo pretreated (5 X  104) 
Unstlmulated, Cyclo pretreated (5 ×  102) 
Unstimulated, Cyclo pretreated (5 ×  104) 
Anti-TNP, 1500 rad (5 ×  102) 
Ant]-TNP, 1500 rad (5 ×  104) 
35 ±  4  0 03 
12± 3  0008 
58 ±  4  NS 
56 ±  4  NS 
28 ±  4  0 02 
13 ±  2  0007 
None  133 ±  7  -- 
AntI-TNP, 1500 rad (105)  76 ±  8  <0 01 
AntI-TNP, 1500 rad (4 ×  10  ~)  61  -t- 1  <0001 
Unstimulated, 1500 rad (10 ~) 
Unstlmulated, 1500 rad (4 ×  l0  s) 
Experiment  Effector cells 
155 ±  12  NS 
138 ±  6  NS 
Assays for cytolysls of 5tCr labeled TNP-modl- 
fled P 815 targets, specific tysis at E T~ 
33.1  100  1 
'70 
1  See Table II 
2  Anti-TNP  6  25 
Unstlmulated  0  0 
5  ×  105  BALB/c  spleen  cells  were  stimulated  in  vitro  with  TNP-KLH,  with  or  without  effector 
lymphocytes  IgM PFC were measured after 4 d  with TNP-coated sheep erythrocytes as indicators  In 
experiment 1, effector lymphocytes were generated by m vitro stimulation and are the same cells as those 
used in the expenment shown m  Table II  In experiment 2,  the effector lymphocytes were induced in 
vtvo as descnbed in  Materials and  Methods  Background  PFC  responses (without  TNP-KLH)  were 
experiment 1,  18 +  2, experiment 2, 24 +  4 
* NS, not stgmficant. 
:~ Spontaneous 51Cr release was <20% 
progress to define  the cellular  target  of these hapten-specific  CTL;  i.e., whether  they 
act on antigen-presenting  cells, helper  T  lymphocytes,  or B  cells; and  the role of H-2- 
encoded  determinants  in this phenomenon. 
Discussion 
Our  results  demonstrate  that  BALB/c  TNP-reactive  effector cells  interact  with  a 
syngeneic  TNP-binding  myeloma,  MOPC  315,  in  the  presence  of a  soluble  TNP- 
protein  conjugate,  the  interaction  being  manifested  as  a  reduction  in  antibody A  K  ABBAS, S  E  RATNOFSKY, AND S  J  BURAKOFF  319 
secretion  by the  myeloma targets.  The effector cells are  hapten-specific and  H-2- 
restricted, Thy-l-bearing,  Ly-2-positive T  cells,  and  they only recognize myeloma 
targets that bind the hapten-proteins to specific surface receptors. 
One of the initial questions raised by these experiments is the nature of the effector 
cells and precisely what effect they have on the myeloma targets. Although in vitro 
stimulation  of lymphocytes with TNP-modified syngeneic cells  generates  not  only 
CTL but hapten-specific suppressor T  cells as well (8), the phenotypic characteristics 
of the  effect cells  detected in  our system  are  typical of CTL.  Thus,  the  cells  are 
radioresistant,  and  their  precursors  are  insensitive  to  Cyclo treatment  (Table  II). 
Secondly, the hapten specificity of DNP-  and TNP-reactive CTL, as measured  by 
51Cr release, closely parallels the specificity of these same cells as far as interaction 
with  MOPC  315  cells in  the  presence of DNP-KLH and TNP-KLH is concerned 
(Table VII). Thirdly, the effector cells cannot be bound to TNP-protein-coated plastic 
dishes (data not shown) under conditions that have been shown to bind a  variety of 
hapten- and idiotype-specific suppressor T  cells but  not  CTL  (17,  30, 31).  Finally, 
TNP-specifie CTL generated in vivo (25) also inhibit MOPC 315 cells in the presence 
of TNP-KLH,  albeit  to  a  lesser  degree  than  effectors induced  in  vitro,  probably 
because the in vivo protocol induces relatively weak CTL (data not shown). Taken 
together, these data support the view that the effector cells that  inhibit MOPC 315 
targets in the presence of TNP-KLH are TNP-specifie CTL. Our inability to detect 
significant lysis of myeloma targets after this coculture by 5XCr-release  assays or by 
dye exclusion is probably because these latter techniques are relatively insensitive and 
measure late consequences of CTL-target interactions  In fact, functional inactivation 
of myeloma targets may be an early effect of CTL and  has been used as a  highly 
sensitive assay for classical, alloreactive CTL (19,  20). It is also noteworthy that the 
51Cr-release assay we have utilized is only a  4-h assay, whereas cocultures that  are 
undertaken to measure effects on myeloma cell function are done for 24 h. So far, we 
have been unable to do 24-h SlCr-release assays because of high spontaneous release 
of ~lCr from the myeloma targets. In any event, it is likely that the myeloma targets 
that  are incubated with soluble TNP-KLH and TNP-specific CTL, and  that show 
inhibition of antibody secretion, are committed to lyse, and  the reduced viable-cell 
recoveries after 2-3 d of reculture are consistent with this view. 
Irrespective of the  ultimate  fate of myeloma cells, the ability of hapten-reactive 
CTL to inhibit myeloma function in the presence of soluble hapten-protein conjugates 
has  several important  implications.  One central observation  is  that  only myeloma 
cells  that  bind  the  hapten  to  specific  surface  receptors  are  susceptible  to  such 
regulation,  implying that  receptor-bound antigen  forms an essential component of 
the target moiety recognized by the T  cells. This is clearly different from the results 
of Schmitt-Verhulst et al. (9) and Ballas and Henney (10), who have shown that only 
with  H-2  k mice, soluble TNP-protein  conjugates can  generate TNP-reactive, H-2- 
restricted CTL and sensitize a variety of non-TNP-binding tumor targets for lysis by 
such  CTL.  In  our studies,  with  H-2  a effectors and  targets,  only the TNP-binding 
myeloma MOPC 315 serves as a target for TNP-specific CTL in the presence of TNP- 
KLH (Table VIII A). Moreover, ABA-specific CTL do not affect myeloma function 
in the presence of ABA-KLH (Table IX), and these findings cannot be attributed to 
significant quantitative differences in the binding of different antigens to the myeloma 
targets. Most strikingly, ABA-specific CTL do interact with MOPC  315 cells in the 320  CYTOLYTIC T  LYMPHOCYTE  REGULATION OF  MYELOMA CELLS 
presence of the double conjugate TNP-ABA-KLH, strongly indicating that binding 
of antigens to specific surface receptors is necessary to render the cells suppressible by 
hapten-reactive CTL. The second key observation is that the TNP-reactive CTL are 
H-2 restricted, in that only H-2  a effectors inhibit MOPC 315 cells (Table V) and only 
TNP-modified  H-2  a  cold  targets  are  effective blockers  (Table  VI).  This  result  is 
consistent with the view that  H-2-encoded surface determinants constitute another 
component of the target structure recognized by hapten-reactive CTE, similar to the 
proposed interaction of virus- or hapten-reactive CTL with appropriate virus-infected 
or hapten-modified syngeneic targets (7, 32). Thus, it appears that TNP-specific CTL 
recognize TNP-KLH bound to specific receptors on MOPC  315 cells in association 
with H-2-encoded  antigens, and  this  lymphocyte-target cell  interaction leads  to  a 
detectable inhibition of antibody secretion by the myeloma cells.  In B lymphocytes, 
it  is clear that surface immunoglobulin and H-2  antigens are  independent surface 
macromolecules (33), and it is likely that immunoglobulin receptors for antigen and 
H-2 determinants on myeloma cells are also not directly linked in any fashion. Our 
results,  therefore, imply that  two  independent  membrane  moieties,  viz.,  receptor- 
bound ligand and H-2 antigens, can be recognized as one functional unit by T  cells. 
Because both antigen receptors  and  H-2  antigens are  freely mobile in the plasma 
membrane, it is conceivable that they come into intimate association after antigen 
binding. These results, therefore, do not shed any light on whether the receptor on the 
T  cell recognizes target  structures as one or two entities, and, hence, whether the 
functional T  cell receptor  has  a  dual specificity for antigen  (or  hapten)  and  H-2 
determinants or a single specificity for modified H-2 determinants. 
Finally, these experiments provide the first direct demonstration of recognition of 
receptor-bound antigens by H-2-restricted T lymphocytes. To the extent that myeloma 
cells are analogous to normal B lymphocytes and antibody-secreting cells (11,  12), 
these results imply that associative recognition of H-2 determinants and of antigen on 
specific B  cells may be an important mechanism whereby antigen-reactive T  ceils 
regulate immune responses specifically. Preliminary experiments (Table X) do indi- 
cate that TNP-specific CTL can regulate an anti-TNP antibody response in vitro, 
although  we  have  not  yet  formally established  the cellular  targets  of such  CTL. 
Clearly a similar mechanism is likely to be operative in situations where H-2-restricted, 
antigen-specific T  cells interact with other antigen-specific immunocompetent cells, 
such as the postulated 1-region-restricted collaboration between antigen-specific helper 
T  and B lymphocytes (5, 6). The myeloma system provides a model for exploring in 
greater depth the mechanisms of and requirements for regulatory interactions between 
T  lymphocytes and other immunocompetent cells m  which both cell types are H-2 
restricted and antigen specific. 
Summary 
BALB/c splenocytes stimulated in vitro with trinitrophenyl (TNP)-modified syn- 
geneic cells inhibit the secretion of antibody by the TNP-binding BALB/c myeloma 
MOPC 315 in the presence of soluble TNP-Keyhole limpet hemocyanin (KLH). The 
effector cells  are  hapten-specific,  H-2-restricted,  Thy-l.2-bearing,  Ly-2-positive T 
lymphocytes whose precursors are resistant to pretreatment with cyclophosphamide. 
These phenotypic properties  are typical of hapten-specific cytolytic T  lymphocytes 
(CTL). The TNP-reactive CTL that inhibit MOPC  315  cells fail to suppress  H-2  d A. K. ABBAS, S  E.  RATNOFSKY, AND S  J  BURAKOFF  321 
myelomas that do not bear TNP-specific surface receptors, and this is not attributable 
to differences in total binding of TNP-KLH to the different myeloma cells. Moreover, 
azobenzene arsonate (ABA)-specific CTL inhibit MOPC 315 cells in the presence of 
the double conjugate TNP-ABA-KLH, but not in the presence of soluble TNP-KLH 
or ABA-KLH. These  results  show that  H-2-restricted,  hapten-specific lymphocytes 
regulate the function of myeloma cells that bind the hapten only to specific surface 
receptors, and provide a model for associative recognition of surface H-2 determinants 
and receptor-bound antigen. The results are discussed with reference to the mecha- 
nisms of T  lymphocyte-target cell  interactions,  and  the possible  physiologic role of 
hapten-reactive CTL in specifically regulating anti-hapten antibody responses. 
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